Presented by BioPharm Process Associates…

Slow today…let’s see what happened….

• The U.S. has set aside $1B for H1N1 Flu (Swine Flu) vaccine production…Sanofi, GSK and Novartis to benefit. [WSJ]

• Aastrom Biosciences stops a mid-stage cell therapy trial after a patient dies, Aastrom shares drop. The cells are injected directly into the heart muscle and are being studied for CHF. [Reuters]

• Icahn and Eastbourne Capital get support from fellow shareholder P. Schoenfeld and Associates in proxy battle with Amylin Pharmaceuticals. [New York Times - DealBook]

• FDA finally accepts SkyePharma’s long-delayed application to sell Flutiform, an asthma drug. [TimesOnline]

• Two big PDUFA’s coming up: J&J and Bayer’s Xarelto and GSK and Genmab’s Arzerra. [FierceBiotech]

• The FDA has granted Fast Track status to Enobia Pharma’s ENB-0040 for the treatment of hypophosphatasia (HPP). [ FierceBiotech]

• Finally, Derek Lowe from In The Pipeline addresses all the shareholder he PO’ed when he ranted on Arena Pharmaceuticals’ lorcaserin. After getting some serious heat, Derek responds — check it out! [Corante]

Anonymous Tip? Comments? Contact us at: hr@iguanabio.com

Image from primezone

Related Posts